Comparison of amyloid plaque contrast generated by T2‐weighted, T  2* ‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease

One of the hallmark pathologies of Alzheimer's disease (AD) is amyloid plaque deposition. Plaques appear hypointense on T2‐weighted and T  2* ‐weighted MR images probably due to the presence of endogenous iron, but no quantitative comparison of various imaging techniques has been reported. We estimated the T1, T2, T  2* , and proton density values of cortical plaques and normal cortical tissue and analyzed the plaque contrast generated by a collection of T2‐weighted, T  2* ‐weighted, and susceptibility‐weighted imaging (SWI) methods in ex vivo transgenic mouse specimens. The proton density and T1 values were similar for both cortical plaques and normal cortical tissue. The T2 and T  2* values were similar in cortical plaques, which indicates that the iron content of cortical plaques may not be as large as previously thought. Ex vivo plaque contrast was increased compared to a previously reported spin‐echo sequence by summing multiple echoes and by performing SWI; however, gradient echo and SWI were found to be impractical for in vivo imaging due to susceptibility interface–related signal loss in the cortex. Magn Reson Med, 2009. © 2009 Wiley‐Liss, Inc.

[1]  R M Henkelman,et al.  Contrast, resolution, and detectability in MR imaging. , 1991, Journal of computer assisted tomography.

[2]  J C Gore,et al.  The Loss of Small Objects in Variable TE Imaging: Implications for FSE, RARE, and EPI , 1992, Magnetic resonance in medicine.

[3]  Susumu Mori,et al.  Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[4]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[5]  M. Dhenain,et al.  Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice , 2007, Magnetic resonance in medicine.

[6]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[7]  Richard A. Robb,et al.  A Software System for Interactive and Quantitative Analysis of Biomedical Images , 1990 .

[8]  Andrew J Wheaton,et al.  In vivo measurement of plaque burden in a mouse model of Alzheimer's disease , 2006, Journal of magnetic resonance imaging : JMRI.

[9]  Carlo Ciulla,et al.  Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain , 2007, Journal of magnetic resonance imaging : JMRI.

[10]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[11]  R Gruetter,et al.  Automatic, localized in Vivo adjustment of all first‐and second‐order shim coils , 1993, Magnetic resonance in medicine.

[12]  Michael Garwood,et al.  In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent , 2004, Magnetic resonance in medicine.

[13]  Marc Dhenain,et al.  Senile plaques do not induce susceptibility effects in T 2*‐weighted MR microscopic images , 2002, NMR in biomedicine.

[14]  Marc Dhenain,et al.  Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice , 2009, Neurobiology of Aging.

[15]  Clifford R Jack,et al.  In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice , 2005, The Journal of Neuroscience.

[16]  Benjamin Zahneisen,et al.  Gradient‐echo and CRAZED imaging for minute detection of Alzheimer plaques in an APPV717I × ADAM10‐dn mouse model , 2007, Magnetic resonance in medicine.

[17]  Yu-Chung N. Cheng,et al.  Susceptibility weighted imaging (SWI) , 2004, Zeitschrift fur medizinische Physik.

[18]  Thomas Wisniewski,et al.  Magnetic Resonance in Medicine 51:794–798 (2004) MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease , 2022 .

[19]  G A Johnson,et al.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Marc Dhenain,et al.  Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease , 2006, Neurobiology of Disease.

[21]  Reinhard Schliebs,et al.  Longitudinal assessment of Alzheimer's β‐amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging , 2006, Journal of magnetic resonance imaging : JMRI.

[22]  Joseph A. Helpern,et al.  Histological Co-Localization of Iron in Aß Plaques of PS/APP Transgenic Mice , 2005, Neurochemical Research.

[23]  M. F. Falangola,et al.  Visualization of β‐amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents , 2004, Magnetic resonance in medicine.

[24]  A Van der Linden,et al.  Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease , 2005, Magnetic resonance in medicine.

[25]  S. Pizer,et al.  3D Imaging in Medicine , 1990, NATO ASI Series.

[26]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .